GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IR-Med Inc (OTCPK:IRME) » Definitions » LT-Debt-to-Total-Asset

IRME (IR-Med) LT-Debt-to-Total-Asset : 0.29 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IR-Med LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. IR-Med's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.29.

IR-Med's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.29). It may suggest that IR-Med is progressively becoming more dependent on debt to grow their business.


IR-Med LT-Debt-to-Total-Asset Historical Data

The historical data trend for IR-Med's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IR-Med LT-Debt-to-Total-Asset Chart

IR-Med Annual Data
Trend Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
0.08 0.06 0.01 0.16

IR-Med Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.16 0.28 0.18 0.29

IR-Med LT-Debt-to-Total-Asset Calculation

IR-Med's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.161/0.999
=

IR-Med's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0.155/0.533
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IR-Med  (OTCPK:IRME) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


IR-Med LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of IR-Med's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


IR-Med Business Description

Traded in Other Exchanges
N/A
Address
Z.H.R Industrial Zone, P.O. Box 143, Rosh Pina, ISR, 1231400
IR-Med Inc is a development stage medical device company developing its technology through its Subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with Artificial Intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time.